In this issue of Neuron, Cruchaga et al. (2013) identify genetic variability linked to altered levels of tau protein in cerebrospinal fluid. They show that the same genetic variants can also confer risk for Alzheimer's disease.
There is now a series of standard tools for the generation and analysis of -ome-scale human genotype data. Many scientific questions have been asked using these methods, but most have focused on the traditional case-control genome-wide association (GWA) study (Hardy and Singleton, 2009 ). In the context of Alzheimer's disease (AD) such approaches have successfully identified a considerable number of loci that harbor risk variants for disease (Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2009; Naj et al., 2011; Seshadri et al., 2010) . A fairly standard approach to getting more out of these data is to analyze increasingly larger cohorts; increasing n leads to greater power and a finer resolution of the genetic basis of disease. In this issue of Neuron, Cruchaga et al. (2013) describe an alternate approach, leveraging the power of genetics to find variability that modulates a disease-relevant endophenotype, and in turn using these results to identify risk alleles for AD.
The notion of endophenotype as a route to understanding the basis of disease is one that has received considerable attention in recent years, particularly in the field of psychiatric genetics (Cruchaga et al., 2012; Hinrichs et al., 2010; Kauwe et al., 2007 Kauwe et al., , 2008 . The concept is simple and centers on addressing a problem that is particularly acute in late onset disorders: the temporal distance between initiation of a disease process and clinical presentation is a long one. In this time, myriad factors may alter the underlying disease process, including those within genetic, epigenetic, environmental, and stochastic spheres; consequently, the ultimate outcome (i.e., disease presentation) can be highly variable. The endophenotype is meant to sit in the gap between this alpha and omega, and in the best case is a measure that directly-rather than indirectly-reflects the progression of the underlying disease process. Measuring an intermediate diseaserelated event offers critical advantages over readouts of clinical presentation; such intermediate events can serve as preclinical biomarkers of disease or as a method to track progression. Because it is more proximal to the underlying disease process, and probably a more objective readout, intermediate events also may have less innate variance.
In the current work, Cruchaga et al. (2013) performed a GWA study on 1,300 cerebrospinal fluid (CSF) samples measured for both tau and tau phosphorylated at threonine 181 (ptau), both of which are established biomarkers for AD. As expected, Cruchaga et al. (2013) showed that variability at APOE was significantly associated with CSF levels of both tau and ptau. Notably, however, they also provide evidence that this association is in part independent of Ab 42 levels in CSF, suggesting a route between APOE alleles and tau levels that is not mediated by Ab 42 . However, the central finding of this article was the identification of three novel genetic loci associated with CSF ptau or tau levels, at 3q28, 9p24.2, and 6p21.1. Interestingly, the latter resides over the TREM gene cluster, including TREM2, which was recently shown to contain rare risk alleles for AD (Guerreiro et al., 2013; Jonsson et al., 2013) . Investigating this locus further showed that while the rare AD risk variant at TREM2 (p.R47H) was indeed associated with CSF ptau and tau levels, there were at least three independent alleles associated with CSF tau/ptau at this gene cluster. Besides APOE, none of the tau/ptau-influencing loci identified here were associated with CSF Ab levels.
Based on the notion that understanding biomarkers for disease will ultimately tell us more about the disease process, Cruchaga et al. (2013) took the next logical step and analyzed the identified variants for association with AD, tau pathology, and cognitive decline. They show that variability at 3q28 associated with CSF tau/ptau was also linked to risk for AD, cognitive decline, and to levels of neurofibrillary tangle pathology. Although not quite as complete, the same type of effect was previously noted at the TREM gene cluster on 6p21.1, where TREM2 alleles had been associated with disease (Guerreiro et al., 2013; Jonsson et al., 2013) . Lastly, Cruchaga et al. (2013) failed to find evidence that the alleles linked to CSF tau/ptau at 9p24.2 conferred risk for AD, cognitive decline, or AD pathology. There are many potential reasons why this locus failed to associate with disease. For instance, the tau/ptau association could simply be a type I errorcommon in GWA, particularly in singlestage designs with modest samples size. More intriguingly, however, is the possibility that the effect allele at this locus alters tau/ptau levels through a mechanism unrelated to the disease process. While Cruchaga et al. (2013) attempt to address this by testing whether this locus is broadly associated with protein clearance from the CSF, this does not preclude a more specific effect on tau/ptau clearance. Such a finding may tell us little about disease risk but may prove useful in improving the information provided by biomarkers. Identifying variants that alter biomarkers for disease without altering risk offers the opportunity to condition biomarker levels based on nondiseaserelated genetic variability and thus improves the utility of these protein measures in predicting and tracking disease (by removing/reducing biomarker variance unrelated to disease). While in isolation the effect of the particular allele identified here is too small to have much consequence on such an analysis, as more alleles are identified, this may prove to be a valuable approach.
Thus, of the four loci reported to influence CSF tau/ptau, three show robust evidence for also altering risk for AD. In each instance the direction of effect on CSF tau and ptau, and on risk for AD, cognitive decline, and tangle pathology was consistent; alleles associated with lower tau and ptau were associated with reduced risk for AD, slower cognitive decline, and reduced neurofibrillary tangle pathology. While this is an exciting piece of work that supports the idea of using endophenotype to understand the basis of disease, there is still much to do. There exist exciting opportunities and challenges in taking the current findings further. GWA studies identify loci, not genes, and as such a critical next step is to identify the pathobiologically relevant gene (or genes) at the 3q28 locus and TREM gene cluster and determine the effect of these risk alleles on that gene. For the most part, the risk alleles associated by GWA are not linked to protein-coding variability, and in all likelihood they confer their effects by altering transcript expression. While Cruchaga et al. (2013) went some way toward testing this-by examining the effect of the identified alleles on expression of proximal transcripts-this small exploratory study requires further work. Given the recent identification of TREM2 as a risk gene for AD, the identification of multiple independent alleles at this locus that alter CSF tau/ptau is particularly exciting, and further fine-scale investigation of this locus is certainly warranted in AD.
Lastly, by Cruchaga et al. (2013) 's own calculations, the four loci linked with CSF tau/ptau levels only explain a minor proportion of the variability in CSF tau/ ptau, indicating that at least some of the remaining variability can be attributed to as-yet-unknown genetic variants. Thus, there are clearly more risk alleles to be found. It is likely that the best route to identify these unknown factors will employ a combination of genetic methods, including GWA and secondgeneration sequencing. There is certainly great promise in these methods; however, analyzing cohorts of sufficient size will be critical; approximately 1,300 CSF samples are an impressive amount, but making substantive future gains in this area will probably require larger cohorts and unified biological measures.
In summary, Cruchaga et al. (2013) have taken an exciting step in showing that the endophenotype is a valuable and informative measure for understanding disease. Their work has provided valuable new insight into the basis of AD and promises to be the impetus for addressing a new series of research questions in this field. Given their findings, this effort certainly appears to be a valuable addition to the massive consortium-based case control analyses.
